| Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT ML Sorror, MB Maris, R Storb, F Baron, BM Sandmaier, DG Maloney, ... Blood 106 (8), 2912-2919, 2005 | 3107 | 2005 |
| HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide L Luznik, PV O'Donnell, HJ Symons, AR Chen, MS Leffell, M Zahurak, ... Biology of Blood and Marrow Transplantation 14 (6), 641-650, 2008 | 2061 | 2008 |
| Defining the intensity of conditioning regimens: working definitions A Bacigalupo, K Ballen, D Rizzo, S Giralt, H Lazarus, V Ho, J Apperley, ... Biology of blood and marrow transplantation 15 (12), 1628-1633, 2009 | 1952 | 2009 |
| Reduced mortality after allogeneic hematopoietic-cell transplantation TA Gooley, JW Chien, SA Pergam, S Hingorani, ML Sorror, M Boeckh, ... New England Journal of Medicine 363 (22), 2091-2101, 2010 | 1747 | 2010 |
| Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects PA McSweeney, D Niederwieser, JA Shizuru, BM Sandmaier, AJ Molina, ... Blood, The Journal of the American Society of Hematology 97 (11), 3390-3400, 2001 | 1690 | 2001 |
| Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research S Giralt, K Ballen, D Rizzo, A Bacigalupo, M Horowitz, M Pasquini, ... Biology of Blood and Marrow Transplantation 15 (3), 367-369, 2009 | 891 | 2009 |
| Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation M Mielcarek, PJ Martin, W Leisenring, MED Flowers, DG Maloney, ... Blood 102 (2), 756-762, 2003 | 699 | 2003 |
| Conditioning regimens for hematopoietic cell transplantation: one size does not fit all B Gyurkocza, BM Sandmaier Blood, The Journal of the American Society of Hematology 124 (3), 344-353, 2014 | 690 | 2014 |
| Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning T Fukuda, M Boeckh, RA Carter, BM Sandmaier, MB Maris, DG Maloney, ... Blood 102 (3), 827-833, 2003 | 599 | 2003 |
| Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting … D Niederwieser, M Maris, JA Shizuru, E Petersdorf, U Hegenbart, ... Blood, The Journal of the American Society of Hematology 101 (4), 1620-1629, 2003 | 539 | 2003 |
| Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma DG Maloney, AJ Molina, F Sahebi, KE Stockerl-Goldstein, BM Sandmaier, ... Blood 102 (9), 3447-3454, 2003 | 497 | 2003 |
| Comorbidity and disease status–based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell … ML Sorror, BM Sandmaier, BE Storer, MB Maris, F Baron, DG Maloney, ... Journal of Clinical Oncology 25 (27), 4246-4254, 2007 | 482 | 2007 |
| Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation ML Sorror, RF Storb, BM Sandmaier, RT Maziarz, MA Pulsipher, MB Maris, ... Journal of Clinical Oncology 32 (29), 3249-3256, 2014 | 452 | 2014 |
| Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning F Baron, MB Maris, BM Sandmaier, BE Storer, M Sorror, R Diaconescu, ... Journal of clinical oncology 23 (9), 1993-2003, 2005 | 436 | 2005 |
| Cord-blood transplantation in patients with minimal residual disease F Milano, T Gooley, B Wood, A Woolfrey, ME Flowers, K Doney, ... New England Journal of Medicine 375 (10), 944-953, 2016 | 430 | 2016 |
| Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission RB Walter, SA Buckley, JM Pagel, BL Wood, BE Storer, BM Sandmaier, ... Blood, The Journal of the American Society of Hematology 122 (10), 1813-1821, 2013 | 408 | 2013 |
| HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies MB Maris, D Niederwieser, BM Sandmaier, B Storer, M Stuart, D Maloney, ... Blood 102 (6), 2021-2030, 2003 | 401 | 2003 |
| Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study ML Green, W Leisenring, HU Xie, TC Mast, Y Cui, BM Sandmaier, ... The Lancet Haematology 3 (3), e119-e127, 2016 | 400 | 2016 |
| Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors R Diaconescu, CR Flowers, B Storer, ML Sorror, MB Maris, DG Maloney, ... Blood 104 (5), 1550-1558, 2004 | 393 | 2004 |
| Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of … ML Sorror, MB Maris, B Storer, BM Sandmaier, R Diaconescu, C Flowers, ... Blood 104 (4), 961-968, 2004 | 387 | 2004 |
